📰 Abt News
Page 189 - Abt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Abt. Real-time updates on events, politics, business and more.
March 30, 2023
Janiczek Wealth Management LLC cut its holdings in Abbott Laboratories (NYSE:ABT – Get Rating) by 10.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,576 shares of the healthcare product maker’s stock after selling 177 shares during the period. Janiczek Wealth Management LLC’s holdings […]
March 30, 2023
Arcblock (ABT) traded 4.5% higher against the dollar during the one day period ending at 19:00 PM E.T. on March 29th. Over the last week, Arcblock has traded down 1.6% against the dollar. Arcblock has a total market cap of $12.40 million and approximately $280,307.82 worth of Arcblock was traded on exchanges in the last […]
March 30, 2023
Arcblock (ABT) traded up 7.9% against the U.S. dollar during the 1 day period ending at 11:00 AM E.T. on March 30th. In the last seven days, Arcblock has traded up 1.5% against the U.S. dollar. Arcblock has a market cap of $13.20 million and approximately $510,726.90 worth of Arcblock was traded on exchanges in […]
March 30, 2023
Abbott Laboratories (NYSE:ABT – Get Rating) had its price target cut by Bank of America from $125.00 to $115.00 in a note issued to investors on Thursday, The Fly reports. Bank of America‘s price target points to a potential upside of 16.61% from the stock’s current price. Several other equities analysts also recently issued reports […]
March 30, 2023
Strategic Advisors LLC reduced its position in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 33.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,426 shares of the healthcare product maker’s stock after selling 11,964 shares during the period. Strategic Advisors LLC’s […]
March 30, 2023
Cambridge Advisors Inc. trimmed its position in Abbott Laboratories (NYSE:ABT – Get Rating) by 2.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 8,690 shares of the healthcare product maker’s stock after selling 200 shares during the period. Cambridge Advisors Inc.’s holdings in Abbott Laboratories were […]
March 30, 2023
Graybill Bartz & Assoc Ltd. increased its position in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,508 shares of the healthcare product maker’s stock after purchasing an additional 582 shares during […]
March 30, 2023
Investment Management of Virginia LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,299 shares of the healthcare product maker’s stock after selling 770 shares during the period. Investment Management of […]
March 30, 2023
Culbertson A N & Co. Inc. decreased its position in Abbott Laboratories (NYSE:ABT – Get Rating) by 0.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 96,478 shares of the healthcare product maker’s stock after selling 587 shares during the period. Abbott Laboratories comprises approximately 2.2% of […]
March 29, 2023
Alta Wealth Advisors LLC bought a new position in Abbott Laboratories (NYSE:ABT – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,309 shares of the healthcare product maker’s stock, valued at approximately $253,000. Other institutional investors and hedge funds have […]